IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors
Adult T-cell leukemia/lymphoma (ATL) is an aggressive T-cell neoplasia associated with human T-cell leukemia virus type 1 (HTLV-1) infection and has an extremely poor prognosis. Lenalidomide (LEN; a second-generation immunomodulatory drug [IMiD]) has been employed as an additional therapeutic option...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English English |
| Published: |
Frontiers Media SA
2024
|
| Subjects: | |
| Online Access: | https://eprints.ums.edu.my/id/eprint/38798/1/ABSTRACT.pdf https://eprints.ums.edu.my/id/eprint/38798/2/FULL%20TEXT.pdf |
| _version_ | 1825715597818724352 |
|---|---|
| author | Yu Wang Shunsuke Shimosaki Emi Ikebe Hidekatsu Iha Jun-ichi Yamamoto Nichole Fife Tomonaga Ichikawa Mitsuo Hori Masao Ogata Yoshiyuki Tsukamoto Naoki Hijiya Masatsugu Moriyama Shotaro Hagiwara Shuichi Kusano Masumichi Saito Kamruddin Ahmed Akira Nishizono Hiroshi Handa Kazuhiro Morishita |
| author_facet | Yu Wang Shunsuke Shimosaki Emi Ikebe Hidekatsu Iha Jun-ichi Yamamoto Nichole Fife Tomonaga Ichikawa Mitsuo Hori Masao Ogata Yoshiyuki Tsukamoto Naoki Hijiya Masatsugu Moriyama Shotaro Hagiwara Shuichi Kusano Masumichi Saito Kamruddin Ahmed Akira Nishizono Hiroshi Handa Kazuhiro Morishita |
| author_sort | Yu Wang |
| collection | UMS |
| description | Adult T-cell leukemia/lymphoma (ATL) is an aggressive T-cell neoplasia associated with human T-cell leukemia virus type 1 (HTLV-1) infection and has an extremely poor prognosis. Lenalidomide (LEN; a second-generation immunomodulatory drug [IMiD]) has been employed as an additional therapeutic option for ATL since 2017, but its mechanism of action has not been fully proven, and recent studies reported emerging concerns about the development of second primary malignancies in patients treated with long-term IMiD therapy. Our purpose in this study was to elucidate the IMiD-mediated anti-ATL mechanisms. Thirteen ATL-related cell lines were divided into LEN-sensitive or LEN-resistant groups. CRBN knockdown (KD) led to a loss of LEN efficacy and IKZF2-KD-induced LEN efficacy in resistant cells. DNA microarray analysis demonstrated distinct transcriptional alteration after LEN treatment between LEN-sensitive and LEN-resistant ATL cell lines. Oral treatment of LEN for ATL cell-transplanted severe combined immunodeficiency (SCID) mice also indicated clear suppressive effects on tumor growth. Finally, a novel cereblon modulator (CELMoD), iberdomide (IBE), exhibited a broader and deeper spectrum of growth suppression to ATL cells with efficient IKZF2 degradation, which was not observed in other IMiD treatments. Based on these findings, our study strongly supports the novel therapeutic advantages of IBE against aggressive and relapsed ATL. |
| first_indexed | 2024-09-24T00:49:22Z |
| format | Article |
| id | ums.eprints-38798 |
| institution | Universiti Malaysia Sabah |
| language | English English |
| last_indexed | 2024-09-24T00:49:22Z |
| publishDate | 2024 |
| publisher | Frontiers Media SA |
| record_format | dspace |
| spelling | ums.eprints-387982024-06-10T06:46:39Z https://eprints.ums.edu.my/id/eprint/38798/ IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors Yu Wang Shunsuke Shimosaki Emi Ikebe Hidekatsu Iha Jun-ichi Yamamoto Nichole Fife Tomonaga Ichikawa Mitsuo Hori Masao Ogata Yoshiyuki Tsukamoto Naoki Hijiya Masatsugu Moriyama Shotaro Hagiwara Shuichi Kusano Masumichi Saito Kamruddin Ahmed Akira Nishizono Hiroshi Handa Kazuhiro Morishita R5-920 Medicine (General) RC254-282 Neoplasms. Tumors. Oncology Including cancer and carcinogens RC633-647.5 Diseases of the blood and blood-forming organs Adult T-cell leukemia/lymphoma (ATL) is an aggressive T-cell neoplasia associated with human T-cell leukemia virus type 1 (HTLV-1) infection and has an extremely poor prognosis. Lenalidomide (LEN; a second-generation immunomodulatory drug [IMiD]) has been employed as an additional therapeutic option for ATL since 2017, but its mechanism of action has not been fully proven, and recent studies reported emerging concerns about the development of second primary malignancies in patients treated with long-term IMiD therapy. Our purpose in this study was to elucidate the IMiD-mediated anti-ATL mechanisms. Thirteen ATL-related cell lines were divided into LEN-sensitive or LEN-resistant groups. CRBN knockdown (KD) led to a loss of LEN efficacy and IKZF2-KD-induced LEN efficacy in resistant cells. DNA microarray analysis demonstrated distinct transcriptional alteration after LEN treatment between LEN-sensitive and LEN-resistant ATL cell lines. Oral treatment of LEN for ATL cell-transplanted severe combined immunodeficiency (SCID) mice also indicated clear suppressive effects on tumor growth. Finally, a novel cereblon modulator (CELMoD), iberdomide (IBE), exhibited a broader and deeper spectrum of growth suppression to ATL cells with efficient IKZF2 degradation, which was not observed in other IMiD treatments. Based on these findings, our study strongly supports the novel therapeutic advantages of IBE against aggressive and relapsed ATL. Frontiers Media SA 2024 Article NonPeerReviewed text en https://eprints.ums.edu.my/id/eprint/38798/1/ABSTRACT.pdf text en https://eprints.ums.edu.my/id/eprint/38798/2/FULL%20TEXT.pdf Yu Wang and Shunsuke Shimosaki and Emi Ikebe and Hidekatsu Iha and Jun-ichi Yamamoto and Nichole Fife and Tomonaga Ichikawa and Mitsuo Hori and Masao Ogata and Yoshiyuki Tsukamoto and Naoki Hijiya and Masatsugu Moriyama and Shotaro Hagiwara and Shuichi Kusano and Masumichi Saito and Kamruddin Ahmed and Akira Nishizono and Hiroshi Handa and Kazuhiro Morishita (2024) IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors. Frontiers in Oncology, 13. pp. 1-13. ISSN 2234-943X https://doi.org/10.3389/fonc.2023.1272528 |
| spellingShingle | R5-920 Medicine (General) RC254-282 Neoplasms. Tumors. Oncology Including cancer and carcinogens RC633-647.5 Diseases of the blood and blood-forming organs Yu Wang Shunsuke Shimosaki Emi Ikebe Hidekatsu Iha Jun-ichi Yamamoto Nichole Fife Tomonaga Ichikawa Mitsuo Hori Masao Ogata Yoshiyuki Tsukamoto Naoki Hijiya Masatsugu Moriyama Shotaro Hagiwara Shuichi Kusano Masumichi Saito Kamruddin Ahmed Akira Nishizono Hiroshi Handa Kazuhiro Morishita IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors |
| title | IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors |
| title_full | IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors |
| title_fullStr | IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors |
| title_full_unstemmed | IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors |
| title_short | IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors |
| title_sort | imid celmod induced growth suppression of adult t cell leukemia lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors |
| topic | R5-920 Medicine (General) RC254-282 Neoplasms. Tumors. Oncology Including cancer and carcinogens RC633-647.5 Diseases of the blood and blood-forming organs |
| url | https://eprints.ums.edu.my/id/eprint/38798/1/ABSTRACT.pdf https://eprints.ums.edu.my/id/eprint/38798/2/FULL%20TEXT.pdf |
| work_keys_str_mv | AT yuwang imidcelmodinducedgrowthsuppressionofadulttcellleukemialymphomacellsviacereblonthroughdownregulationoftargetproteinsandtheirdownstreameffectors AT shunsukeshimosaki imidcelmodinducedgrowthsuppressionofadulttcellleukemialymphomacellsviacereblonthroughdownregulationoftargetproteinsandtheirdownstreameffectors AT emiikebe imidcelmodinducedgrowthsuppressionofadulttcellleukemialymphomacellsviacereblonthroughdownregulationoftargetproteinsandtheirdownstreameffectors AT hidekatsuiha imidcelmodinducedgrowthsuppressionofadulttcellleukemialymphomacellsviacereblonthroughdownregulationoftargetproteinsandtheirdownstreameffectors AT junichiyamamoto imidcelmodinducedgrowthsuppressionofadulttcellleukemialymphomacellsviacereblonthroughdownregulationoftargetproteinsandtheirdownstreameffectors AT nicholefife imidcelmodinducedgrowthsuppressionofadulttcellleukemialymphomacellsviacereblonthroughdownregulationoftargetproteinsandtheirdownstreameffectors AT tomonagaichikawa imidcelmodinducedgrowthsuppressionofadulttcellleukemialymphomacellsviacereblonthroughdownregulationoftargetproteinsandtheirdownstreameffectors AT mitsuohori imidcelmodinducedgrowthsuppressionofadulttcellleukemialymphomacellsviacereblonthroughdownregulationoftargetproteinsandtheirdownstreameffectors AT masaoogata imidcelmodinducedgrowthsuppressionofadulttcellleukemialymphomacellsviacereblonthroughdownregulationoftargetproteinsandtheirdownstreameffectors AT yoshiyukitsukamoto imidcelmodinducedgrowthsuppressionofadulttcellleukemialymphomacellsviacereblonthroughdownregulationoftargetproteinsandtheirdownstreameffectors AT naokihijiya imidcelmodinducedgrowthsuppressionofadulttcellleukemialymphomacellsviacereblonthroughdownregulationoftargetproteinsandtheirdownstreameffectors AT masatsugumoriyama imidcelmodinducedgrowthsuppressionofadulttcellleukemialymphomacellsviacereblonthroughdownregulationoftargetproteinsandtheirdownstreameffectors AT shotarohagiwara imidcelmodinducedgrowthsuppressionofadulttcellleukemialymphomacellsviacereblonthroughdownregulationoftargetproteinsandtheirdownstreameffectors AT shuichikusano imidcelmodinducedgrowthsuppressionofadulttcellleukemialymphomacellsviacereblonthroughdownregulationoftargetproteinsandtheirdownstreameffectors AT masumichisaito imidcelmodinducedgrowthsuppressionofadulttcellleukemialymphomacellsviacereblonthroughdownregulationoftargetproteinsandtheirdownstreameffectors AT kamruddinahmed imidcelmodinducedgrowthsuppressionofadulttcellleukemialymphomacellsviacereblonthroughdownregulationoftargetproteinsandtheirdownstreameffectors AT akiranishizono imidcelmodinducedgrowthsuppressionofadulttcellleukemialymphomacellsviacereblonthroughdownregulationoftargetproteinsandtheirdownstreameffectors AT hiroshihanda imidcelmodinducedgrowthsuppressionofadulttcellleukemialymphomacellsviacereblonthroughdownregulationoftargetproteinsandtheirdownstreameffectors AT kazuhiromorishita imidcelmodinducedgrowthsuppressionofadulttcellleukemialymphomacellsviacereblonthroughdownregulationoftargetproteinsandtheirdownstreameffectors |